Sanofi GCVRZ 深 沪
已收盘 03-26 16:00:00 美东时间
0.8711
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 总市值 1113.52亿
- 52周最高 0.882
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 总股本 1278.30亿
- 历史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.153
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Novavax Stock Is Trading Higher On Wednesday?
Novavax shares rise after Q1 revenue beat; partnerships, credit facility, and technical levels shape outlook amid shift to net loss.
05-07 03:07
Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification DURHAM, N.C., May 6, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organi...
05-07 00:42
Novavax Q1 2026 Earnings Call Transcript
Novavax (NASDAQ:NVAX) released first-quarter financial results and hosted an ea...
05-06 21:54
FACTBOX-Global pharma companies that have publicly announced Trump drug pricing agreements
FACTBOX-Global pharma companies that have publicly announced Trump drug pricing agreements Changes dateline, updates paragraph 1, adds Regeneron's deal details May 4 (Reuters) - U.S. President Donald Trump secured agreements with 17 major pharmaceutical companies to bring U.S. prescription drug pric
05-04 22:45
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms Changes dateline, updates paragraph 1, adds Amgen's investment May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on
05-04 21:45
Guangdong HEC Pharma wins FDA approval for insulin glargine injection Langlara
Guangdong HEC Pharma wins FDA approval for insulin glargine injection Langlara Guangdong HEC Pharmaceutical won U.S. FDA marketing clearance for insulin glargine injection Langlara, labeled as interchangeable with Sanofi’s Lantus. Lannett holds exclusive U.S. sales rights for insulin glargine, with
05-04 08:02
Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe
Regeneron beats Q1 estimates as Eylea HD demand rises, while margins narrow and FDA decisions on manufacturing remain pending.
04-30 01:57
Regeneron drops despite Q1 beat, $3B share buyback program
Regeneron Pharmaceuticals (REGN) lost ~2% in the premarket on Wednesday despite reporting better-than-expected Q1 2026 financials and concurrently announcing a new share buyback program worth up to $3...
04-29 21:17
